Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation

P. Kala, M. Miklovič, Š. Jíchová, P. Škaroupková, Z. Vaňourková, H. Maxová, O. Gawrys, E. Kompanowska-Jezierska, J. Sadowski, JD. Imig, JR. Falck, J. Veselka, L. Červenka, R. Aiglová, M. Vícha, V. Gloger, M. Táborský

. 2021 ; 9 (8) : . [pub] 20210820

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024112

Grantová podpora
68121 Univerzita Karlova v Praze
17-28220A Ministerstvo Zdravotnictví Ceské Republiky
I-0011 Welch Foundation

This study evaluates the effects of chronic treatment with EET-A, an orally active epoxyeicosatrienoic acid (EETs) analog, on the course of aorto-caval fistula (ACF)-induced heart failure (HF) in Ren-2 transgenic rats (TGR), a model characterized by hypertension and augmented activity of the renin-angiotensin system (RAS). The results were compared with standard pharmacological blockade of the RAS using angiotensin-converting enzyme inhibitor (ACEi). The rationale for employing EET-A as a new treatment approach is based on our findings that apart from increased RAS activity, untreated ACF TGR also shows kidney and left ventricle (LV) tissue deficiency of EETs. Untreated ACF TGR began to die 17 days after creating ACF and were all dead by day 84. The treatment with EET-A alone or ACEi alone improved the survival rate: in 156 days after ACF creation, it was 45.5% and 59.4%, respectively. The combined treatment with EET-A and ACEi appeared to improve the final survival to 71%; however, the difference from either single treatment regimen did not reach significance. Nevertheless, our findings support the notion that targeting the cytochrome P-450-dependent epoxygenase pathway of arachidonic acid metabolism should be considered for the treatment of HF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024112
003      
CZ-PrNML
005      
20211013134044.0
007      
ta
008      
211006s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/biomedicines9081053 $2 doi
035    __
$a (PubMed)34440257
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kala, Petr $u Department of Cardiology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, 150 06 Prague, Czech Republic $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
245    10
$a Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation / $c P. Kala, M. Miklovič, Š. Jíchová, P. Škaroupková, Z. Vaňourková, H. Maxová, O. Gawrys, E. Kompanowska-Jezierska, J. Sadowski, JD. Imig, JR. Falck, J. Veselka, L. Červenka, R. Aiglová, M. Vícha, V. Gloger, M. Táborský
520    9_
$a This study evaluates the effects of chronic treatment with EET-A, an orally active epoxyeicosatrienoic acid (EETs) analog, on the course of aorto-caval fistula (ACF)-induced heart failure (HF) in Ren-2 transgenic rats (TGR), a model characterized by hypertension and augmented activity of the renin-angiotensin system (RAS). The results were compared with standard pharmacological blockade of the RAS using angiotensin-converting enzyme inhibitor (ACEi). The rationale for employing EET-A as a new treatment approach is based on our findings that apart from increased RAS activity, untreated ACF TGR also shows kidney and left ventricle (LV) tissue deficiency of EETs. Untreated ACF TGR began to die 17 days after creating ACF and were all dead by day 84. The treatment with EET-A alone or ACEi alone improved the survival rate: in 156 days after ACF creation, it was 45.5% and 59.4%, respectively. The combined treatment with EET-A and ACEi appeared to improve the final survival to 71%; however, the difference from either single treatment regimen did not reach significance. Nevertheless, our findings support the notion that targeting the cytochrome P-450-dependent epoxygenase pathway of arachidonic acid metabolism should be considered for the treatment of HF.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Miklovič, Matúš $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, 150 06 Prague, Czech Republic
700    1_
$a Jíchová, Šárka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Škaroupková, Petra $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Vaňourková, Zdeňka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Maxová, Hana $u Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, 150 06 Prague, Czech Republic
700    1_
$a Gawrys, Olga $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland
700    1_
$a Kompanowska-Jezierska, Elzbieta $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland
700    1_
$a Sadowski, Janusz $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland
700    1_
$a Imig, John D $u Drug Discovery Center, Medical College of Wisconsin, Wauwatosa, WI 53226, USA
700    1_
$a Falck, John R $u Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
700    1_
$a Veselka, Josef $u Department of Cardiology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, 150 06 Prague, Czech Republic
700    1_
$a Červenka, Luděk $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, 150 06 Prague, Czech Republic
700    1_
$a Aiglová, Renáta $u Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, I.P. Pavlova 185/6, Nová Ulice, 779 00 Olomouc, Czech Republic
700    1_
$a Vícha, Marek $u Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, I.P. Pavlova 185/6, Nová Ulice, 779 00 Olomouc, Czech Republic
700    1_
$a Gloger, Vít $u Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, I.P. Pavlova 185/6, Nová Ulice, 779 00 Olomouc, Czech Republic
700    1_
$a Táborský, Miloš $u Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, I.P. Pavlova 185/6, Nová Ulice, 779 00 Olomouc, Czech Republic
773    0_
$w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 9, č. 8 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34440257 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013134041 $b ABA008
999    __
$a ind $b bmc $g 1708193 $s 1144609
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 9 $c 8 $e 20210820 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
GRA    __
$a 68121 $p Univerzita Karlova v Praze
GRA    __
$a 17-28220A $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a I-0011 $p Welch Foundation
LZP    __
$a Pubmed-20211006

Najít záznam

Citační ukazatele

Možnosti archivace